The Conversation (0)
Pieris Pharmaceuticals released their financial results for the third quarter of 2017.
Pieris Pharmaceuticals (NASDAQ:PIRS) released their financial results for the third quarter of 2017.
As quoted in the press release:
“During the third quarter, we continued to execute on our pipeline and actively engage with strategic partners, with the advancement of our lead immuno-oncology drug candidate PRS-343 into the clinic and continued progression of lead assets under our alliances with AstraZeneca and Servier in respiratory disease and immuno-oncology,” said Stephen S. Yoder, President and CEO of Pieris. “PRS-343 marks the first 4-1BB-based bispecific to reach clinical development, a significant milestone for our Company and a demonstration of our leadership in T-cell costimulatory receptor biology. In addition, we expect to initiate the PRS-060 first-in-human study during the fourth quarter of this year, which would result in advancing three compounds in various stages of clinical development during 2017. I am very proud of the diligent efforts of our employees in Munich and Boston to have made this possible. Next year, we look forward to sharing data from our clinical studies and updating investors on additional program selections within our growing proprietary pipeline and strategic alliances.”
Click here to read the full press release.
Source: www.marketwired.com
